265 related articles for article (PubMed ID: 15498146)
41. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.
Vose JM; Bierman PJ; Loberiza FR; Bociek RG; Matso D; Armitage JO
Leuk Lymphoma; 2007 Apr; 48(4):683-90. PubMed ID: 17454625
[TBL] [Abstract][Full Text] [Related]
42. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Grillo-López AJ
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
[TBL] [Abstract][Full Text] [Related]
43. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
[TBL] [Abstract][Full Text] [Related]
44. Future directions in radioimmunotherapy for B-cell lymphoma.
Horning SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Riley MB; Gordon LI
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):8-13. PubMed ID: 15160856
[TBL] [Abstract][Full Text] [Related]
46. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Exp Hematol; 2007 Apr; 35(4):534-40. PubMed ID: 17379063
[TBL] [Abstract][Full Text] [Related]
47. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
[TBL] [Abstract][Full Text] [Related]
48. Yttrium 90 ibritumomab tiuxetan in lymphoma.
Cheung MC; Haynes AE; Stevens A; Meyer RM; Imrie K;
Leuk Lymphoma; 2006 Jun; 47(6):967-77. PubMed ID: 16840185
[TBL] [Abstract][Full Text] [Related]
49. Logistics of therapy with the ibritumomab tiuxetan regimen.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
[TBL] [Abstract][Full Text] [Related]
50. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
51. New strategies in radioimmunotherapy for lymphoma.
Pandit-Taskar N; Hamlin PA; Reyes S; Larson SM; Divgi CR
Curr Oncol Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12895386
[TBL] [Abstract][Full Text] [Related]
52. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
[TBL] [Abstract][Full Text] [Related]
53. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
Ghobrial I; Witzig T
Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
[TBL] [Abstract][Full Text] [Related]
54. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
Bischof Delaloye A
Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
[TBL] [Abstract][Full Text] [Related]
55. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
56. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
Vose JM; Bierman PJ; Enke C; Hankins J; Bociek G; Lynch JC; Armitage JO
J Clin Oncol; 2005 Jan; 23(3):461-7. PubMed ID: 15534357
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Borghaei H; Schilder RJ
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):4-9. PubMed ID: 14762738
[TBL] [Abstract][Full Text] [Related]
58. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
[TBL] [Abstract][Full Text] [Related]
59. 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
Blum KA; Bartlett NL
Expert Opin Biol Ther; 2004 Aug; 4(8):1323-31. PubMed ID: 15268665
[TBL] [Abstract][Full Text] [Related]
60. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Weigert O; Illidge T; Hiddemann W; Dreyling M
Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]